DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Saura C, Oliveira M, Feng YH. et al.
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
J Clin Oncol 2019;
DOI: 10.1200/JCO.2019.37.15:suppl.1002.
We do not assume any responsibility for the contents of the web pages of other providers.